Relative risk including 95% confidence intervals (CIs) and observed number of cancers of selected haematopoietic sites by time of follow up in the Swedish Inpatient Register RA cohort 1990–2003. Relative risks comparing the cohort with the Swedish general population, adjusting for age, sex, and calendar period
| Site (ICD code) | No observed, relative risk (95% CI) by time with RA* | |||||
|---|---|---|---|---|---|---|
| No | 1–4 years | No | 5–9 years | No | 10+ years | |
| *Counting from date of first discharge listing RA. | ||||||
| CLL, chronic lymphocytic leukaemia. | ||||||
| All haematopoietic malignancies | 129 | 1.5 (1.2 to 1.8) | 98 | 1.5 (1.2 to 1.8) | 154 | 1.5 (1.3 to 1.7) |
| Malignant lymphoma including CLL | 80 | 1.6 (1.2 to 1.9) | 68 | 1.7 (1.3 to 2.2) | 102 | 1.7 (1.4 to 2.0) |
| Plasma cell neoplasms | 14 | 0.9 (0.5 to 1.5) | 7 | 0.6 (0.2 to 1.2) | 13 | 0.7 (0.4 to 1.1) |
| Leukaemia excluding CLL | 30 | 1.9 (1.3 to 2.7) | 21 | 1.7 (1.1 to 2.7) | 38 | 2.0 (1.4 to 2.8) |
| Acute lymphatic leukaemia | 1 | 1.5 (0.0 to 8.2) | 0 | 0.0 (0.0 to 7.1) | 0 | 0.0 (0.0 to 4.5) |
| Acute myeloid leukaemia | 19 | 2.2 (1.3 to 3.5) | 12 | 1.8 (0.9 to 3.2) | 22 | 2.1 (1.3 to 3.2) |
| Chronic myeloid leukaemia | 2 | 1.2 (0.1 to 4.4) | 4 | 3.2 (0.9 to 8.1) | 7 | 3.6 (1.5 to 7.5) |
| Other or undefined leukaemia | 8 | 1.7 (0.7 to 3.4) | 5 | 1.4 (0.5 to 3.3) | 8 | 1.4 (0.6 to 2.8) |
| Polycytaemia vera | 5 | 1.5 (0.5 to 3.5) | 2 | 0.8 (0.1 to 2.8) | 1 | 0.2 (0.0 to 1.3) |